Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @Xconomy
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Xconomy
-
Prikvačeni tweet
Sign up for our new free newsletters for industry news, insight, and analysis: https://mailchi.mp/xconomy.com/subscribe-twitter-profile …
#Xconomists#XconXpertise#XconBioRoundup#XcelerateLS#XconSD#XconSF#XconNY#XconBOS#XconSEA#XconPHIpic.twitter.com/BW5Oav6cRA
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Arcutis Bio Raises $159M in Upsized IPO to Test Skin Disease Drugs - by
@sarahdc https://xconomy.com/san-diego/2020/01/31/arcutis-bio-raises-159m-in-upsized-ipo-to-test-skin-disease-drugs/ …$ARQTHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Xconomy proslijedio/la je Tweet
ICYMI,
@aimmune won FDA approval Friday for#Palforzia, a peanut allergy therapy. The FDA decision covers kids 4-17 yrs.old... https://xconomy.com/san-francisco/2020/01/31/aimmune-awarded-first-fda-approval-for-a-peanut-allergy-therapy/ …$AIMTHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Xconomy proslijedio/la je Tweet
#Palforzia carries an $890 a month wholesale price before any rebates or discounts. But@aimmune says it will offer payment assistant programs that could reduce the cost to as low as $20 a month. The new drug is expected to launch in coming weeks.Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Xconomy proslijedio/la je Tweet
Xconomy: BIO Report: More Work Needed to Improve Diversity at Biotech Firms
#Diversity#biotech#diversityinSTEM via@diversityup@cafepharma@Chefsache@Xconomy@_timos_ https://j.mp/36WkRLj pic.twitter.com/DnZ0NiufDQ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BIO Report: More Work Needed to Improve Diversity at Biotech Firms - by
@sarahdchttps://xconomy.com/national/2020/01/30/bio-report-more-work-needed-to-improve-diversity-at-biotech-firms/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Xconomy proslijedio/la je Tweet
When it comes to
#CRISPR, size matters. Here's why@mammothbiosci thinks the smaller size of Cas14 gives it advantages for developing new drugs and diagnosticshttps://xconomy.com/san-francisco/2020/01/30/with-45m-mammoth-bio-expects-big-things-from-tiny-crispr-cas14/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
[PARTNER EVENT]
@NYCHBL presents 7th annual Healthcare Investment Trends: Where Will the Money Flow in 2020? Use code HCVC-PARTNER for $25 discount on registration. REGISTER: http://bit.ly/hcvc2020partner Sponsored by@BDOhealth#HCVC2020Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Newly added
#XconSD#XcelerateLS speakers include: Ciara Kennedy of@AmplyxPharma Chris Loryman of@UCSDInnovation Russ Barrans of@Evofem Josh Schimmer of Evercore https://xconomy.com/xcelerating-life-sciences-san-diego/ …pic.twitter.com/8zp9PZHaJx
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
With $45M,
@mammothbiosci Expects Big Things From Tiny CRISPR Cas14 - by@frankvinluan; insight from CEO@martintrevor_https://xconomy.com/san-francisco/2020/01/30/with-45m-mammoth-bio-expects-big-things-from-tiny-crispr-cas14/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Black Diamond’s Upsized IPO Raises $201M to Advance Its Cancer Drug R&D - by
@frankvinluan https://xconomy.com/boston/2020/01/30/black-diamonds-upsized-ipo-raises-201m-to-advance-its-cancer-drug-rd/ …$BDTXHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Vizgen Launches With $14M to Market New Subcellular Imaging Technique - by
@sarahdchttps://xconomy.com/boston/2020/01/30/vizgen-launches-with-14m-to-market-new-subcellular-imaging-technique/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Spun out the
#XconomyAwards where Nancy Hopkins won the Lifetime Achievement Award, 3@MIT scientists formed the Boston Biotech Working Group to "remedy the gender imbalance in biotech": https://www.statnews.com/2020/01/29/biotechs-missing-women/ …@snbhatia@SusanHockfieldHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Annovis Bio Gets $12M in IPO to Target Trio of Neurotoxic Proteins - by
@sarahdc https://xconomy.com/new-york/2020/01/29/annovis-bio-gets-12m-in-ipo-to-target-trio-of-neurotoxic-proteins/ …$ANVSHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Xconomy proslijedio/la je Tweet
Lack of good
#CDMOs a factor for@KrystalBiotech in investing $70-90m into internal PA gene therapy plant https://buff.ly/2Obgc1e pic.twitter.com/wqhhN650eL
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Xconomy proslijedio/la je Tweet
Calling all
#Starups
Are you looking to engage with #biopharma executives and#investors? Apply to pitch at this year’s Startup Spotlight during#BIOEuropeSpring. The deadline to apply is this Friday, January 31! >> http://ebdgroup.formstack.com/forms/?3673559-bQOQpjzsfb&_ga=2.175469154.1150738558.1580094181-1440400942.1556918554&_gac=1.11323136.1577985105.EAIaIQobChMI9ZCDyrTl5gIVGKSzCh3rPg5eEAAYASAAEgLGOPD_BwE …pic.twitter.com/EL0sfhPySc
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Xconomy proslijedio/la je Tweet
This
@AcceleronPharma drug didn't pan out treating a rare blood disorder or chronic kidney disease. But with positive topline Phs 2 data in#pulmonaryarterialhypertension, some now see blockbuster potential.$XLRN shares shot up 50% Tues. https://xconomy.com/boston/2020/01/28/third-times-the-charm-as-acceleron-drug-shows-early-promise-in-pah/ …#PAHHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Xconomy proslijedio/la je Tweet
When developing a new therapy how do you keep in complete control of its manufacturing? This whitepaper looks at what to consider - whatever path you take.http://spr.ly/601015Ham
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Xconomy proslijedio/la je Tweet
Attend the 14th Annual Hub and SPP Model Optimization event, which will feature manufacturers, pharmacies, PBMs and more, on February 24-26, 2020, at the Loews Philadelphia Hotel. Register today!
@InformaConnect#conferencehttps://informaconnect.com/hub-and-spp-model-optimization/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@SpringBankPharm Ends Hepatitis B Work After Death in Clinical Trial - by@frankvinluan https://xconomy.com/boston/2020/01/29/spring-bank-pharma-ends-hepatitis-b-work-after-death-in-clinical-trial/ …$SBPHHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.